Showing results (61-70 of 253) with videos related to

Sort By:
Pageof 26
Blood Advances|December 6, 2023
Dietary risk factors for monoclonal gammopathy of undetermined significance in a racially diverse populationJanine M Joseph, Jens Hillengass, Li Tang, et al.
Frontiers in Immunology|September 5, 2024
Cost-per-responder analysis of patients with lenalidomide-refractory multiple myeloma receiving ciltacabtagene autoleucel in CARTITUDE-4Doris K Hansen, Xiaoxiao Lu, Omar Castaneda Puglianini, et al.
Blood|January 12, 2013
Prognostic implications of serial 18-fluoro-deoxyglucose emission tomography in multiple myeloma treated with total therapy 3Saad Z Usmani, Alan Mitchell, Sarah Waheed, et al.
Blood Cancer Journal|February 20, 2025
High WEE1 expression is independently linked to poor survival in multiple myelomaAnish K Simhal, Ross S Firestone, Jung Hun Oh, et al.
Clinical Lymphoma, Myeloma & Leukemia|October 16, 2024
Addition of Elotuzumab to Backbone Treatment Regimens for Multiple Myeloma: An Updated Meta-Analysis of Randomized Clinical TrialsBruno Almeida Costa, Thomaz Alexandre Costa, Gabriel Cavalcante Lima Chagas, et al.
JAMA Oncology|January 6, 2018
Autologous Transplantation for Newly Diagnosed Multiple Myeloma in the Era of Novel Agent Induction: A Systematic Review and Meta-analysisBinod Dhakal, Aniko Szabo, Saurabh Chhabra, et al.
Blood|March 14, 2019
A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myelomaJoseph Mikhael, Paul Richardson, Saad Z Usmani, et al.
Current Medical Research and Opinion|March 19, 2015
Patterns of total cost and economic consequences of progression for patients with newly diagnosed multiple myelomaSteven R Arikian, Dejan Milentijevic, Gary Binder, et al.
Lancet (London, England)|July 20, 2020
Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for patients with relapsed or refractory multiple myeloma (CANDOR): results from a randomised, multicentre, open-label, phase 3 studyMeletios Dimopoulos, Hang Quach, Maria-Victoria Mateos, et al.
Blood Cancer Journal|March 22, 2022
Extramedullary disease in multiple myeloma: a systematic literature reviewJoan Bladé, Meral Beksac, Jo Caers, et al.
Pageof 26